People · Operator
Named in public records as an officer, director or promoter · active 2014–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| MBX Biosciences, Inc. | — | Pharmaceuticals | Series C | $74.8M | $724.1M | 2019 |
| Mb2 Llc | — | Pharmaceuticals | Seed | $1.5M | $57.1M | 2014 |
Peter Kent Hawryluk at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Kent Hawryluk on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick M. Heron | 1 | 3 |
| James M. Cornelius | 1 | 2 |
| Edward M. Mathers | 1 | 1 |
| Richard Kent DiMarchi | 1 | 1 |
| Tiba M. Aynechi | 1 | 1 |
| Ora Kent Pescovitz | 1 | 1 |
| Carl M. Gordon | 1 | 1 |
| Richard M. Bartram | 1 | 1 |
| Timothy Kent Knickerbocker | 1 | 1 |
| Richard Dennis DiMarchi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.